4th Quarter - Report

AVENUE SOLUTIONS for GENENTECH USA, INC.

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation; Issues related to Medicare Part B, CMS coverage and reimbursement; Issues related to insulin out of pocket costs; S. 954, Affordable Insulin Now Act of 2023; S. 1269, INSULIN Act of 2023; Issues related to healthcare access, quality and costs; Issues related to orphan drugs; Senate Finance Committees Better Mental Health Care, Lower Cost Drugs and Extenders Act (Discussion Draft); S. 2973, The Modernizing and Ensuring PBM Accountability (MEPA) Act; H.R. 5378, The Lower Costs, More Transparency Act

LobbyistCovered position, as disclosed
ELIZABETH MACDONALD BARNETT —
TRACY SPICER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5378 (118th), S. 1269 (118th), S. 954 (118th), S. 2973 (118th)

Health Issues HCR

Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization; Issues related to 340b drug pricing program; Expiring healthcare extenders; S. 1339, The Pharmacy Benefit Manager Reform Act

LobbyistCovered position, as disclosed
ELIZABETH MACDONALD BARNETT —
TRACY SPICER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1339 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.